Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

9904	Companies
199558	Keywords
130424	Articles
106063	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 09/16/2025 at 12:00, 5 months 5 days ago

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Moderna reports 8-fold increase in neutralizing antibodies with Spikevax 2025-2026 formula, reinforcing FDA approval. Clinical trial data supports efficacy against COVID-19 LP.8.1 variant

FDA Approval COVID-19 Vaccine Moderna Spikevax Neutralizing Antibodies
BRIEF

published on 09/02/2025 at 13:05, 5 months 19 days ago

Moderna to Present mRNA Therapeutics Data at 2025 ICIEM

MRNA Therapeutics Moderna Propionic Acidemia ICIEM Methylmalonic Acidemia
PRESS RELEASE

published on 09/02/2025 at 13:00, 5 months 19 days ago

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
Moderna, Inc. to present abstracts on mRNA therapeutics at the 2025 ICIEM including PA, MMA, and GSD1a programs in Kyoto, Japan. Company's first time presenting data for MMA and GSD1a

Moderna Inc. MRNA Therapeutics ICIEM Abstracts Kyoto Japan
BRIEF

published on 08/27/2025 at 19:29, 5 months 24 days ago

Moderna's Updated COVID-19 Vaccines Approved by U.S. FDA

FDA Approval COVID-19 Vaccine Moderna SARS-CoV-2 Variant Spikevax And MNEXSPIKE
PRESS RELEASE

published on 08/27/2025 at 19:24, 5 months 24 days ago

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
Moderna announces FDA approval for updated Spikevax® and mNEXSPIKE® COVID-19 vaccines targeting LP.8.1 variant to prevent severe outcomes. Vaccines available soon

FDA Approval Moderna COVID-19 Vaccines Spikevax MNEXSPIKE
BRIEF

published on 08/22/2025 at 15:30, 5 months 30 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine

COVID-19 Vaccine Moderna Health Canada Approval Canadian Manufacturing Biomanufacturing Leadership
PRESS RELEASE

published on 08/22/2025 at 15:25, 5 months 30 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna's Spikevax COVID-19 vaccine for SARS-CoV-2 LP.8.1 variant authorized in Canada, with all 2025 doses produced domestically. Leadership in biomanufacturing highlighted

COVID-19 Vaccine Canada Moderna Spikevax Biomanufacturing
BRIEF

published on 08/21/2025 at 13:05, 6 months ago

Moderna to Participate in Major September 2025 Conferences

Investor Conferences MRNA Medicine Moderna Live Webcast Healthcare Presentation
PRESS RELEASE

published on 08/21/2025 at 13:00, 6 months ago

Moderna to Present at Upcoming Conferences in September 2025
Moderna, Inc. to participate in upcoming investor conferences. The company's innovative mRNA technology redefines medicine creation, focusing on infectious diseases, oncology, and more

Investor Conferences Healthcare COVID-19 Vaccine MRNA Technology Moderna
BRIEF

published on 08/01/2025 at 13:05, 6 months 20 days ago

Moderna's Q2 2025 Financial Results and Business Updates

Cost Management FDA Approvals Q2 2025 Revenue Moderna Financial Results Vaccine Sales

Accesswire

Published on 02/21/2026 at 00:45, 15 hours 2 minutes ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 15 hours 17 minutes ago

Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:15, 16 hours 32 minutes ago

DigiPower X Announces Closing of Settlement
Published on 02/20/2026 at 23:00, 16 hours 47 minutes ago

Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 17 hours 30 minutes ago

Organto Foods Completes Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 02/21/2026 at 12:00, 3 hours 47 minutes ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Published on 02/20/2026 at 18:36, 21 hours 10 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 21 hours 16 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 21 hours 24 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 21 hours 47 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

Les Echos

Published on 02/20/2026 at 19:29, 20 hours 18 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 18:00, 21 hours 47 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 09:28, 1 day 6 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
Published on 02/20/2026 at 07:30, 1 day 8 hours ago

Announcement of share buyback in the context of a share purchase plan
Published on 02/20/2026 at 07:30, 1 day 8 hours ago

EURAZEO COMPLETES THE SALE OF EX NIHILO TO L CATTERTON

View all LES ECHOS COMFI WIRE